Johnson And Johnson : A Multi Billion Dollar Company

Intellectual Property: Johnson & Johnson have the rights to many products including: JOHNSON’S® BEBE® PENATEN® PRIM’AGE® JOHNSON’S® BEDTIME™ JOHNSON’S® SOOTHING NATURALS™ DESITIN® NATUSAN® NEUTROGENA® SHOWER TO SHOWER®PIZ BUIN® AVEENO® LUBRIDERM®AMBI® SKINCARE VENDOME® CLEAN & CLEAR® PURPOSE® ROC® ROGAINE® BAND-AID® Brand Adhesive Bandages BENGAY® CALADRYL® PURELL® NEOSPORIN® CORTAID® SAVLON® COMPEED® TUCKS® DAKTARIN® LISTERINE® EFFERDENT® LISTERINE® WHITENING REMBRANDT® REACH® STAYFREE® MONISTAT® CAREFREE® e.p.t.® K-Y® O.B.® TYLENOL® SUDAFED® ROLAIDS® DOLORMIN® MOTRIN® MOTILIUM® MYLANTA® ZYRTEC® and ZYRTEC-D®12-HOUR® BENADRYL® IMODIUM® PEPCID® NICORETTE® SPLENDA® LACTAID® BENECOL® SUN CRYSTALS™ VIACTIV® VISINE® ACUVUE® CONCERTA® REMINYL® /RAZADYNE® TOPAMAX® HALDOL® RISPERDAL® INVEGA® RISPERDAL® CONSTA® DORIBAX™ PREZISTA™ INTELENCE™ RETIN-A MICRO® LEVAQUIN®ORTHOCLONE OKT-3® REMICADE® DURAGESIC® AXERT® ORTHOVISC® ULTRAM® ER Tylenol® with Codeine DITROPAN XL® TERAZOL®ORTHO TRI-CYCLEN®ELMIRON® ORTHO-CYCLEN® ORTHO TRI-CYCLEN® LO ORTHO EVRA® ORTHO-NOVUM®RhoGAM® DACOGEN® PROCRIT® DOXIL® VELCADE® LEUSTATIN® ACIPHEX®/PARIET® REGRANEX® NATRECOR® REOPRO®. They also have the patents and copyrights to a wide array of drugs and medical equipment.

Managers and leaders do not welcome crises because they don't realize that problems and crisis if handled with intelligence become an opportunity for the company. The purpose of writing this paper to discuss the case of "Johnson & Johnson" that became a hero in the eyes of public (Rehak, 2002) and gained their market share back with the help of their effective public relations plan. They accomplished this by making good relations with public and by proving how much they were concerned about the safety of their consumers.

The twenty-first century has seen pharmaceutical companies grow in unprecedented size and strength. Due to the unprecedented growth the larger pharmaceutical companies have gained leverage and power in the prescription drug industry, but they lack innovation to market and they seek ways to help the business continue to increase its profits. The pharmaceutical industry was once ethically sound and was a valuable player in the development of human health. However, overtime with the lack of innovation pharmaceutical companies are becoming an unethical market that exploits patients, doctors and anyone else it can to increase its profitability. With eyes only on profitability this can create a hazard for patients because there

Johnson & Johnson (J&J) was founded 121 years ago based on the need for sterile medical supplies to treat patient’s wounds. Post-operative mortality rates were a grim 90% and after attending a seminar on “antisepsis” Robert Wood Johnson, an apothecary, saw this as an opportunity to start a much needed company. With $100,000 in capital and the help of his brothers, James and Edward, they established Johnson & Johnson. Their prospect with J&J was “to manufacture and sell medical, pharmaceutical, surgical and antiseptic specialties and analgesic goods.”

The FDA behaves in ways that enhance its reputation for protecting consumer safety and public health. As gauged by public opinion polls, the FDA remains one of the most popular agencies in government, regularly securing 70 percent or greater “approval” of its performance among sampled respondents.5 Buttressing this popularity are powerful symbolic lessons of history: The FDA is widely credited with saving thousands of American lives in its response to the sulfanilamide tragedy of 1937 and the thalidomide scandal of 1959–1961.6 Congress dramatically strengthened pharmaceutical regulations after each of these events. Thereby whether or not the agency deserves it, the FDA clearly possesses a reputation for protecting public health and consumer safety.

The Pharmaceutical industry has been in the spotlight for decades due to the fact that they have a reputation for being unethical in its marketing strategies. In The Washington Post Shannon Brownlee (2008) states, “We try never to forget that medicine is for the people. It is not for the profits. The profits follow.” This honorable statement is completely lost in today’s world of pharmaceutical marketing tactics. These tactics are often deceptive and biased. Big Pharma consistently forgets their moral purpose and focuses primarily on the almighty dollar. Big Pharma is working on restoring their reputation by reforming their ethical code of conduct.

Tylenol, an over the counter prescription product from Johnson & Johnson, was one of the top brands in the analgesic market. Within the company, it was also a large income earner that commanded nearly 15% of the company’s total profits. That being the case, the 1982 crisis was not only a big blow to the brand, but also to the company as a whole. The crisis jeopardized the company’s existence; putting at risk a multi million investment which the investors had a lot of faith in. Irrespective of whether the crisis was due to malicious acts from ill motivated criminals or not, the company had to act swiftly to counter the legal issues which were ensuing and mitigate huge impending losses. It was really a trying moment for the top management of Johnson & Johnson and more so to the CEO, James Burke, who faced the toughest test of his managerial career during this time. Though the crisis was amicably solved, there were some legal issues that were imminent and some valuable lessons learnt from the episode.

The purpose of this report is to provide analysis of SEC 10K for Johnson & Johnson (JNJ). JNJ was incorporated in the State of New Jersey in 1887. JNJ and its subsidiaries have approximately 117,900 employees worldwide engaged in the research and development, manufacture and sale of a broad range of 250 operating companies conduction business in all countries of the world. JNJ’s primary focus has been on products related to human health and well-being.

While some have identified Merck as a visionary company dedicated to a "core values and a sense of purpose beyond just making money" (Collins & Porras, 2002, p. 48), others point out corporate misdeeds perpetrated by Merck (e.g., its role in establishing a dubious medical journal that republished articles favorable to Merck products) as contradictory

One of the most important principles of running a business is honesty. However, Johnson & Johnson seem to lack this qualification. For example, Johnson & Johnson released an antipsychotic drug Risperdal in 1993[1]. It gained approval from the

This paper will research the Product recall involving the Drug Company known as Merck, who produced the drug Vioxx use to treat osteoarthritis, and acute pain in adults. Looking at the relationships Merck had with government and lobbyist one can see what actions the drug company may have taken to lead them to this recall. In Addition, This paper will look at the actions Merck took in the approval process and recall of their drug. Using all information provided on this case this paper will decide whether Merck was ethically correct in bringing the drug to market and if they took the right steps in recalling it. Finally I will discuss the other stakeholder responsibilities and provide solutions to prevent this from happening in the future.

In a competitive market to which Johnson and Johnson operates, the smallest of errors can lead to consequences which can cut revenue. When large mistakes occur, millions of dollars are lost, and even worse, there is a loss of customer confidence. Johnson and Johnson has had numerous recalls in their consumer healthcare division recently, which rocked the organization’s once sound image, and diminished its profits. These recalls have hurt Johnson and Johnson’s stocks and cost the company about $900 million in sales last year (Rockoff, 2011).

For CVS’s legal concern, not only do they have to follow federal and state guideline for employees, they have to follow federal guidelines for pharmaceuticals, legal requirements for their nurses, doctors and pharmacist. In addition CVS is expanding into global markets, and that opens them up to foreign legal requirements. Socially, CVS Caremark has a long-standing track record of sound corporate governance and stands firmly committed to acting with integrity and holding

There is full concurrence among the four commentators: Gamgort, Nelson, Thompson, and Sheehan that Bryant Pharmaceuticals should not approve Laura's pitch for a product placement of Seflex on the news program The Morning Show. Undoubtedly, Laura and her Bryant colleagues, along with executive management have an unenviable task; conjuring a "dramatic increase in sales" (Peebles, Ellen. October 2003 P. 32) of Seflex prior to its patent expiration in two years. Yet, the purported solution fails to address serious concerns across three critical issues: "legal, business, and ethical" (Peebles, Ellen. October 2003 P. 40).

In 1886, three brothers, James, Edward, and Robert Johnson, started a multinational healthcare business in New Brunswick, New Jersey. Johnson & Johnson, one of the world’s largest American company, provides diverse healthcare products across the nation. Johnson & Johnson has gained a competitive advantage over most of its competitors because of its leadership in diverse healthcare products. This company offers a plethora of products such as baby care, oral care, skin care, wound care, women health, medical devices, and pharmaceuticals. Robert Wood Johnson crafted the company’s credo, a statement of in which he expresses the company mission of “caring for the world, one person at a time.” (Johnson & Johnson 2015). The company’s credo is very well-structured and very detailed about claiming full responsibility for its employees, doctors, nurses, and patients and also developing a positive business relationship amongst its stakeholders (Johnson & Johnson 2015). Johnson & Johnson is well known for its caring and fair culture to society and corporate environment, however, this company has faced multiple ethical dilemmas which have jeopardized their brand.